Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating

The figure illustrates three key steps for donor hematopoietic stem cells (HSCs) to reconstitute in the recipient's environment and cure patients

Allogeneic hematopoietic stem cell transplantation (allo-HSCT), the pioneer and mainstream form of cellular therapy, represents the only curative or preferred treatment for various malignant and nonmalignant disorders or facilitates organ transplantation by reconstituting the new blood and immune system of a patient with donor’s regenerative HSCs, similar to the comics character “Groot,” who has an incredible regeneration ability. The annual cases of allo-HSCT in mainland China increased from 10042 in 2020 to 12744 in 2021, suggesting that the negative impact of the severe acute respiratory syndrome coronavirus 2 pandemic might be eliminated, while Europe and North American registries reported 18796 and 8326 cases in 2020, respectively.